AB Science (AB.PA) Stock Price

AB Science Price

Euronext·CLOSED
0.73EUR-0.02 (-2.29 %)
Market closed

Revenue has compounded at 8.4% per year over the past 15 years to 1.07 M EUR. AB Science's net margin stands at -730.5%, up from -950.4% several years earlier. Analysts set a median price target of 3.53 EUR, implying 381.5% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus.

AB Science stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of AB Science over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how AB Science stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing AB Science's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

AB Science Stock Price History
DateAB Science Price
7/10/20260.73 EUR
7/9/20260.75 EUR
7/8/20260.74 EUR
7/7/20260.75 EUR
7/6/20260.76 EUR
7/3/20260.76 EUR
7/2/20260.77 EUR
7/1/20260.78 EUR
6/30/20260.88 EUR
6/29/20260.90 EUR
6/26/20260.87 EUR
6/25/20260.86 EUR
6/24/20260.87 EUR
6/23/20260.87 EUR
6/22/20260.87 EUR
6/19/20260.89 EUR
6/18/20260.85 EUR
6/17/20260.88 EUR
6/16/20260.86 EUR
6/15/20260.89 EUR
6/12/20260.89 EUR
6/11/20260.89 EUR
6/10/20260.91 EUR
6/9/20260.89 EUR
6/8/20260.88 EUR
6/5/20260.91 EUR
6/4/20260.93 EUR
6/3/20260.95 EUR
6/2/20260.93 EUR
6/1/20260.95 EUR
5/29/20260.96 EUR
5/28/20260.97 EUR
5/27/20260.96 EUR
5/26/20260.96 EUR
5/25/20260.97 EUR
5/22/20260.95 EUR
5/21/20260.95 EUR
5/20/20260.97 EUR
5/19/20260.96 EUR
5/18/20260.97 EUR
5/15/20261.00 EUR
5/14/20261.02 EUR
5/13/20260.93 EUR
5/12/20260.96 EUR
5/11/20260.98 EUR
5/8/20260.96 EUR
5/7/20260.97 EUR
5/6/20261.00 EUR
5/5/20261.00 EUR
5/4/20261.00 EUR
4/30/20261.06 EUR
4/29/20261.10 EUR
4/28/20261.18 EUR
4/27/20261.16 EUR
4/24/20261.16 EUR
4/23/20261.17 EUR
4/22/20261.17 EUR
4/21/20261.18 EUR
4/20/20261.16 EUR
4/17/20261.16 EUR
4/16/20261.19 EUR
4/15/20261.22 EUR
4/14/20261.21 EUR
4/13/20261.19 EUR
4/10/20261.19 EUR
4/9/20261.20 EUR
4/8/20261.19 EUR
4/7/20261.17 EUR
4/2/20261.18 EUR
4/1/20261.22 EUR
3/31/20261.21 EUR
3/30/20261.17 EUR
3/27/20261.16 EUR
3/26/20261.15 EUR
3/25/20261.16 EUR
3/24/20261.12 EUR
3/23/20261.18 EUR
3/20/20261.20 EUR
3/19/20261.21 EUR
3/18/20261.24 EUR
3/17/20261.24 EUR
3/16/20261.22 EUR
3/13/20261.22 EUR
3/12/20261.25 EUR
3/11/20261.27 EUR
3/10/20261.30 EUR
3/9/20261.25 EUR
3/6/20261.30 EUR
3/5/20261.28 EUR
2/26/20261.36 EUR
2/25/20261.38 EUR
2/23/20261.33 EUR
2/20/20261.34 EUR
2/19/20261.29 EUR
2/18/20261.28 EUR
2/17/20261.28 EUR
2/16/20261.28 EUR
2/13/20261.33 EUR
2/12/20261.34 EUR
2/11/20261.33 EUR
2/10/20261.40 EUR
2/9/20261.37 EUR
2/6/20261.37 EUR
2/5/20261.38 EUR
2/4/20261.40 EUR
2/3/20261.40 EUR
2/2/20261.39 EUR
1/30/20261.42 EUR
1/29/20261.40 EUR
1/28/20261.41 EUR
1/27/20261.42 EUR
1/26/20261.41 EUR
1/23/20261.43 EUR
1/22/20261.44 EUR
1/21/20261.37 EUR
1/20/20261.36 EUR
1/19/20261.39 EUR
1/16/20261.42 EUR
1/15/20261.42 EUR
1/14/20261.42 EUR
1/13/20261.41 EUR
1/12/20261.49 EUR
1/9/20261.49 EUR
1/8/20261.53 EUR
1/7/20261.42 EUR
1/6/20261.40 EUR
1/5/20261.41 EUR
1/2/20261.46 EUR
12/31/20251.47 EUR
12/30/20251.40 EUR
12/29/20251.32 EUR
12/24/20251.29 EUR
12/23/20251.38 EUR
12/22/20251.25 EUR
12/19/20251.28 EUR
12/18/20251.25 EUR
12/17/20251.27 EUR
12/16/20251.23 EUR
12/15/20251.19 EUR
12/12/20251.23 EUR
12/11/20251.21 EUR
12/10/20251.18 EUR
12/9/20251.18 EUR
12/8/20251.22 EUR
12/5/20251.21 EUR
12/4/20251.19 EUR
12/3/20251.16 EUR
12/2/20251.19 EUR
12/1/20251.17 EUR
11/28/20251.19 EUR
11/27/20251.18 EUR
11/26/20251.13 EUR
11/25/20251.14 EUR
11/24/20251.15 EUR
11/21/20251.15 EUR
11/20/20251.15 EUR
11/19/20251.17 EUR
11/18/20251.16 EUR
11/17/20251.16 EUR
11/14/20251.16 EUR
11/13/20251.19 EUR
11/12/20251.19 EUR
11/11/20251.19 EUR
11/10/20251.16 EUR
11/7/20251.15 EUR
11/6/20251.16 EUR
11/5/20251.14 EUR
11/4/20251.17 EUR
11/3/20251.22 EUR
10/31/20251.21 EUR
10/30/20251.17 EUR
10/29/20251.18 EUR
10/28/20251.19 EUR
10/27/20251.20 EUR
10/24/20251.20 EUR
10/23/20251.21 EUR
10/22/20251.25 EUR
10/21/20251.26 EUR
10/20/20251.31 EUR
10/17/20251.27 EUR
10/16/20251.48 EUR
10/15/20251.46 EUR
10/14/20251.35 EUR
10/13/20251.29 EUR
10/10/20251.44 EUR
10/9/20251.40 EUR
10/8/20251.44 EUR
10/7/20251.40 EUR
10/6/20251.32 EUR
10/3/20251.34 EUR
10/2/20251.28 EUR
10/1/20251.26 EUR
9/30/20251.26 EUR
9/29/20251.24 EUR
9/26/20251.25 EUR
9/25/20251.25 EUR
9/24/20251.27 EUR
9/23/20251.27 EUR
9/22/20251.31 EUR
9/19/20251.29 EUR
9/18/20251.26 EUR
9/17/20251.24 EUR
9/16/20251.25 EUR
9/15/20251.25 EUR
9/12/20251.23 EUR
9/11/20251.24 EUR
9/10/20251.24 EUR
9/9/20251.21 EUR
9/8/20251.20 EUR
9/5/20251.21 EUR
9/4/20251.23 EUR
9/3/20251.23 EUR
9/2/20251.24 EUR
9/1/20251.33 EUR
8/29/20251.20 EUR
8/28/20251.21 EUR
8/27/20251.21 EUR
8/26/20251.23 EUR
8/25/20251.28 EUR
8/22/20251.30 EUR
8/21/20251.30 EUR
8/20/20251.32 EUR
8/19/20251.33 EUR
8/18/20251.35 EUR
8/15/20251.34 EUR
8/14/20251.34 EUR
8/13/20251.34 EUR
8/12/20251.34 EUR
8/11/20251.32 EUR
8/8/20251.38 EUR
8/7/20251.29 EUR
8/6/20251.30 EUR
8/5/20251.34 EUR
8/4/20251.40 EUR
8/1/20251.43 EUR
7/31/20251.48 EUR
7/30/20251.49 EUR
7/29/20251.50 EUR
7/28/20251.61 EUR
7/25/20251.39 EUR
7/24/20251.31 EUR
7/23/20251.29 EUR
7/22/20251.22 EUR
7/21/20251.24 EUR
7/18/20251.25 EUR
7/17/20251.29 EUR
7/16/20251.31 EUR
7/15/20251.33 EUR
7/14/20251.37 EUR
Access this data via the Eulerpool API
Get Free API Key

AB Science Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
1.58 M EUR
-14.75 M EUR
-15.05 M EUR
Jan 1, 2021
1.61 M EUR
-13.81 M EUR
-14.46 M EUR
Jan 1, 2022
958,000.00 EUR
-15.94 M EUR
-13.62 M EUR
Jan 1, 2023
970,000.00 EUR
-13.43 M EUR
-11.99 M EUR
Jan 1, 2024
1.07 M EUR
-6.08 M EUR
-7.83 M EUR
Jan 1, 2025 (e)
1.10 M EUR
-22.42 M EUR
-8.86 M EUR
Jan 1, 2026 (e)
1.13 M EUR
-22.73 M EUR
-8.18 M EUR
Jan 1, 2027 (e)
1.34 M EUR
0.00 EUR
0.00 EUR

AB Science Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 13, 2026, 12:32 PM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEk EUR
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
20122013201420152016201720182019202020212022202320242025e2026e2027e
1.001.002.002.001.001.001.001.001.001.00––1.001.001.001.00
––100.00–-50.00–––––––––––
100.00100.0050.0050.00100.00100.00100.00100.00100.00100.00––100.00100.00100.00100.00
1,000.001,000.001,000.001,000.001,000.001,000.001,000.001,000.001,000.001,000.001,000.001,000.001,000.001,000.001,000.001,000.00
-10.00-14.00-16.00-26.00-27.00-27.00-26.00-21.00-15.00-14.00-13.00-11.00-7.00-8.00-8.00–
11.1140.0014.2962.503.85–-3.70-19.23-28.57-6.67-7.14-15.38-36.3614.29––
32.2032.8332.9434.2035.6535.9937.7839.4044.2347.5247.1449.6653.2753.2753.2753.27
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales AB Science generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue AB Science retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare AB Science's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares AB Science has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against AB Science's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

AB Science stock margins

The AB Science margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AB Science. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AB Science.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
95.64 %
-931.71 %
-950.41 %
Jan 1, 2021
93.09 %
-859.24 %
-900.00 %
Jan 1, 2022
96.76 %
-1,663.57 %
-1,421.19 %
Jan 1, 2023
60.52 %
-1,384.43 %
-1,235.57 %
Jan 1, 2024
116.42 %
-567.44 %
-730.50 %
Jan 1, 2025 (e)
116.42 %
-2,040.32 %
-806.32 %
Jan 1, 2026 (e)
116.42 %
-2,006.36 %
-721.96 %
Jan 1, 2027 (e)
116.42 %
0.00 %
0.00 %

AB Science Stock Revenue, EBIT, Earnings per Share

The AB Science earnings per share therefore indicates how much revenue AB Science has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.04 EUR
-0.33 EUR
-0.34 EUR
Jan 1, 2021
0.03 EUR
-0.29 EUR
-0.30 EUR
Jan 1, 2022
0.02 EUR
-0.34 EUR
-0.29 EUR
Jan 1, 2023
0.02 EUR
-0.27 EUR
-0.24 EUR
Jan 1, 2024
0.02 EUR
-0.11 EUR
-0.15 EUR
Jan 1, 2025 (e)
0.02 EUR
-0.42 EUR
-0.13 EUR
Jan 1, 2026 (e)
0.02 EUR
-0.43 EUR
-0.12 EUR
Jan 1, 2027 (e)
0.02 EUR
0.00 EUR
0.00 EUR

AB Science business model & stock analysis

AB Science SA is a biopharmaceutical company based in France that specializes in developing therapies for diseases with high medical need and unmet medical demand. The company was founded in 2001 by Alain Moussy and went public on the Paris stock exchange Euronext in 2010. AB Science SA's business model involves independently conducting research and development of new drugs while also building partnerships with other companies or institutions to optimize the value chain from research to commercialization. AB Science SA is divided into different divisions to specifically address the disease areas to be treated, including oncology and neurology. The company aims to develop innovative drugs based on scientific knowledge that meet the needs of patients suffering from severe and complex diseases. An important aspect of AB Science SA's product range is the quality of the products, with the company working on developing effective and safe therapies. A key component of AB Science SA's product range is the tyrosine kinase inhibitor masitinib. This is used in veterinary medicine and is intended to be used in both dogs and cats suffering from allergic, inflammatory, and oncological diseases. Masitinib is a selective inhibitor of tyrosine kinase that contributes to the regulation of signaling pathways found in cancer cells. It is believed that masitinib plays an important role in modulating the immune system and inhibiting cancer cells, although further studies are needed to confirm the potential therapeutic applications of masitinib. AB Science SA has made significant progress in oncology, particularly in the treatment of gastrointestinal stromal tumors and certain types of malignant tumors that are rare forms of cancer. AB Science SA has now submitted both products for an extended approval request (EA) in collaboration with US Regulatory, achieving the most significant success in the company's history. This could expedite the approval of these two products in the United States. In neurology, AB Science SA has also made significant progress and is currently developing products for the treatment of Alzheimer's disease, multiple sclerosis, and Parkinson's disease. In all of these areas, there is a significant unmet need for safe and effective medications, and AB Science SA is committed to addressing this need through the development of innovative therapies. Overall, AB Science SA is a biopharmaceutical company specializing in the development of therapies to combat diseases with high unmet medical needs. In addition to independent research and development, the company aims to build partnerships with other companies and institutions to optimize the value chain from research to commercialization. The main divisions of the company are oncology and neurology, and it has made significant progress in both areas. The increased submission of approval requests is a significant milestone in the company's history and could lead to further advancement within the industry.

AB Science SWOT Analysis

Strengths

AB Science SA possesses several strengths that contribute to its success:

  • Strong research and development capabilities
  • Robust and innovative product portfolio
  • Proven track record in conducting clinical trials
  • Positive brand reputation in the pharmaceutical industry
  • Strong financial position and ability to invest in new opportunities

Weaknesses

Despite its strengths, AB Science SA also faces certain weaknesses:

  • Dependency on a limited number of key products
  • Reliance on external partnerships for drug development and distribution
  • Lack of geographical diversification in its operations
  • Vulnerability to changes in regulatory frameworks and policies
  • Limited market share compared to larger pharmaceutical companies

Opportunities

AB Science SA can leverage the following opportunities to further its growth:

  • Expanding into new markets and geographical regions
  • Licensing or acquiring complementary technologies or products
  • Leveraging advancements in precision medicine and personalized therapies
  • Collaborating with academic and research institutions to accelerate innovation
  • Taking advantage of government initiatives and funding for research and development

Threats

AB Science SA needs to be cautious of the following potential threats:

  • Intense competition from larger pharmaceutical companies
  • Stringent regulatory requirements and approval processes
  • Economic downturns impacting healthcare budgets and spending
  • Emergence of generic alternatives to AB Science SA's products
  • Technological advancements rendering existing therapies obsolete

AB Science Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

AB Science historical P/E ratio, EBIT multiple, and P/S ratio

AB Science annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

AB Science shares outstanding

The number of shares of AB Science was 53.27 M in 2025. This indicates how many shares AB Science is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
44.23 M Stocks
Jan 1, 2021
47.52 M Stocks
Jan 1, 2022
47.14 M Stocks
Jan 1, 2023
49.66 M Stocks
Jan 1, 2024
53.27 M Stocks
Jan 1, 2025 (e)
53.27 M Stocks
Jan 1, 2026 (e)
53.27 M Stocks
Jan 1, 2027 (e)
53.27 M Stocks

Current AB Science forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
18.20 %
Buy88.89 % (8)
Hold11.11 % (1)
Sell0.00 % (0)
12M Price Target
3.53
Last Price
0.73
Currency
EUR
12M Return Potential
381.47 %
LTM Return
0 %

AB Science Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
9/30/2020-0.16EUR913,499.00EUR2020 Q2
4/30/2020-0.27EUR811,999.00EUR2019 Q4
9/30/2019-0.36EUR710,499.00EUR2019 Q2
8/31/2017-0.46EUR101,499.00EUR2017 Q2
8/31/2016-0.41EUR608,999.00EUR2016 Q2
8/31/2015-0.27EUR1.01 MEUR2015 Q2

EESG©

Eulerpool ESG Scorecard© for the AB Science stock

29/100
33
Environment
15
Social
38
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

AB Science shareholder structure

% Name
20.39595%
Moussy (Alain)
Moussy (Alain)
10.40890%
Marian (Jean-Claude)
Marian (Jean-Claude)
0.11786%
La Française AM
La Française AM
0.00468%
Ursus-3 Capital, AV, S.A
Ursus-3 Capital, AV, S.A
0.00148%
State Street Global Advisors (US)
State Street Global Advisors (US)
0.00000%
Montpensier Arbevel, S.A.S.
Montpensier Arbevel, S.A.S.

AB Science Executives and Management Board

AM

Mr. Alain Moussy

Chairman of the Board, Chief Executive Officer · since 2001

Compensation495,000.00 EUR
DG

Mr. Denis Gicquel

Deputy Chief Executive Officer

Compensation41,000.00 EUR
LG

Mr. Laurent Guy

Chief Financial Officer

PM

Mr. Patrick Moussy

Director

CG

Ms. Cecile de Guillebon

(63)

Independent Director

AB Science Supply Chain

Frequently asked questions about AB Science

AB Science SA is a biopharmaceutical company that focuses on research, development, and commercialization of targeted therapies. Their business model centers around the discovery and development of innovative drugs for various medical conditions, including oncology, neurology, and rare diseases. AB Science SA aims to improve patient outcomes and quality of life by utilizing their proprietary technology and conducting rigorous clinical trials. By combining scientific expertise with a patient-centric approach, AB Science SA strives to bring novel treatments to market, addressing unmet medical needs. With a commitment to innovation and research, AB Science SA continues to pave the way in the field of personalized medicine.

All fundamentals and in-depth analysis of AB Science

Our stock analysis for AB Science stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AB Science. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

AB Science Stock
AB Science Revenue→
AB Science Stock
AB Science Net Income→
AB Science Stock
AB Science P/E→
AB Science Stock
AB Science P/S→
AB Science Stock
AB Science EBIT→
AB Science Stock
AB Science Dividend→
AB Science Stock
AB Science Directors Dealings→
AB Science Stock
AB Science Stocks→
AB Science Stock
AB Science Market capitalization→
AB Science Stock
AB Science Debt→
AB Science Stock
AB Science Liabilities→
AB Science Stock
AB Science Equity→
AB Science Stock
AB Science AAQS→
AB Science Stock
AB Science Employees→
AB Science Stock
AB Science ROE→
AB Science Stock
AB Science ROA→
AB Science Stock
AB Science ROCE→
AB Science Stock
AB Science News→
AB Science Stock
AB Science Analyst Price Targets→

Health Stocks

Ab&B Bio Tech Co Ltd JSAashka HospitalsAbbisko CaymanAarti PharmalabsAbbott IndiaAarti DrugsAbbott LaboratoriesAarey Drugs and PharmaceuticalsAbbVieAardvark TherapeuticsAbcellera BiologicsAap ImplantateAll Stocks A–Z →